

Government of Western Australia North Metropolitan Health Service Women and Newborn Health Service



| ADULT MEDICATION GUIDELINE                                       |                            |  |  |  |  |
|--|----------------------------|--|--|--|--|
| METRONIDAZOLE  |                            |  |  |  |  |
| Scope (Staff):   | All WNHS Staff             |  |  |  |  |
| Scope (Area):  | Obstetrics and Gynaecology |  |  |  |  |
| This document should be read in conjunction with the Disclaimer. |                            |  |  |  |  |

| Quick Links  |                |            |                                |  |  |  |  |  |  |  |
|--|----------------|------------|--------------------------------|--|--|--|--|--|--|--|
| Dose   | Administration | Monitoring | Pregnancy and<br>Breastfeeding |  |  |  |  |  |  |  |
| Restrictions   |                |            |                                |  |  |  |  |  |  |  |
| Formulary: Unrestricted  |                |            |                                |  |  |  |  |  |  |  |
| Medication Class   |                |            |                                |  |  |  |  |  |  |  |
| Nitroimidazole antibiotic  |                |            |                                |  |  |  |  |  |  |  |
| Presentation   |                |            |                                |  |  |  |  |  |  |  |
| Tablet: 200mg, 400mg         Injection: 500mg/100mL         Suppositories: 500mg         Oral Suspension: 200mg/5mL  |                |            |                                |  |  |  |  |  |  |  |
| Storage  |                |            |                                |  |  |  |  |  |  |  |
| Store at room temperature, below 25°C<br>Infusion:<br>Do not freeze.<br>Protect from light during storage; protection from light not required during infusion. |                |            |                                |  |  |  |  |  |  |  |
| Dose   |                |            |                                |  |  |  |  |  |  |  |
| Prophylaxis for gynaecology and urogynaecology surgery IV:   |                |            |                                |  |  |  |  |  |  |  |
| 500mg IV (as a single dose within 60 min (ideally 15-30 min) prior to skin incision  |                |            |                                |  |  |  |  |  |  |  |

Also refer to KEMH Clinical Practice Guideline: Infections: <u>Antibiotic prophylaxis for gynaecology</u> and urogynaecology surgery

### Post-anal sphincter repair

Refer to KEMH Clinical Practice Guideline: O&G: <u>Perineal care and repair: protection</u>, <u>assessment and management</u>

### Prophylaxis for operative vaginal birth

Refer to KEMH Clinical Practice Guideline: O&G: Operative vaginal birth

### **Bacterial vaginosis, trichomoniasis**

Refer to KEMH Clinical Practice Guideline: O&G: Sexually Transmitted Infections (STI)

Refer to KEMH Clinical Practice Guideline: O&G: Vaginal Infections: Antibiotic treatment for

#### Secondary postpartum haemorrhage

Refer to KEMH Clinical Practice Guideline: O&G: Postpartum complications

### Adult and maternal sepsis and septic shock

Refer to KEMH Clinical Practice Guideline: O&G: <u>Sepsis and septic shock: Antibiotics for adult</u> patients at KEMH

### Infections Postpartum

Refer to KEMH Clinical Practice Guideline: O&G: <u>Infections in obstetrics (intra-amniotic</u> <u>chorioamnionitis and postpartum infection)</u>: <u>Diagnosis and mangement</u>

#### Prophylaxis for reinfusion of processed vaginal blood

Refer to KEMH Clinical Practice Guideline: O&G: Intraoperative cell salvage

#### Prophylaxis for hysterosalpingogram for infertility

Refer to KEMH Clinical Practice Guideline: O&G: Infections: Antibiotic prophylaxis/medication: Hysterosalpingogram for infertility

# Administration

# IV infusion

Refer to the Australian Injectable Drugs Handbook

## Oral tablet

To be taken with food

### Oral suspension

To be taken one hour BEFORE food

# Monitoring

Monitor blood count and neurotoxic reactions when treating for >10 days

# Pregnancy

1<sup>st</sup> Trimester: Consider alternative\*

2<sup>nd</sup> Trimester: Considered safe to use

3<sup>rd</sup> Trimester: Considered safe to use

\*Maternal use is not associated with increased risk of congenital malformations or adverse pregnancy outcomes. Mutagenic effects in bacteria and carcinogenic effects in animals have not been confirmed in human studies.

# Breastfeeding

Considered safe to use

May cause some bitterness in milk. Use in divided doses after breastfeeding rather than single daily doses.

# Comments

Avoid alcohol during treatment and for 24 hours after finishing the course to prevent nausea; vomiting, flushing, headache and palpitations.

There is good oral (70–90%) and rectal (60–80%) bioavailability.

# **Related Policies, Procedures & Guidelines**

#### HDWA Mandatory Policies:

WA Adult Medicines Formulary

#### WNHS Clinical Practice Guidelines:

Antimicrobial Stewardship

Gynaecology (Non-oncological)

### WNHS Pharmaceutical and Medicines Management Guidelines:

**Medication Administration** 

Prescribing by Eligible Private Practicing Midwives with a Scheduled Medicines Endorsement

KEMH Services Pharmacy: Medicines and breastfeeding

## References

Australian Medicines Handbook. Metronidazole. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2021 [cited 2021 May 19]. Available from: https://amhonline.amh.net.au/

Therapeutic Guidelines. Metronidazole In: eTG complete [Internet]. West Melbourne (Victoria): Therapeutic Guidelines; 2021 [cited 2021 Apr 12]. Available from: https://tgldcdp-tg-org-au.kelibresources.health.wa.gov.au/etgAccess

The Royal Women's Hospital. Metronidazole. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2021 [cited 2021 May 19]. Available from: <u>https://thewomenspbmg.org.au/</u>

<u>Silver book – STI/BBV management guidelines</u>

| Keywords   | Metronidazole, flagyl, PID, pelvic inflammatory disease, trichomoniasis, BV, bacterial vaginosis, hysterosalpingogram, HSG, surgical prophylaxis, sepsis, perineal repair, operative vaginal delivery |                    |          |   |              |          |  |  |
|--|---|--------------------|----------|---|--------------|----------|--|--|
| Document<br>Owner:   | Chief Pharmacist  |                    |          |   |              |          |  |  |
| Author/<br>Reviewer  | KEMH Pharmacy Department  |                    |          |   |              |          |  |  |
| Version<br>Info:   | Dec 2017 – full review<br>Dec 2020 – full review<br>May 2021 - antimicrobial dosing included in guideline for surgical prophylaxis, links<br>updated  |                    |          |   |              |          |  |  |
| Date First<br>Issued:  | July 2015   | Last Reviewed:     | May 2021 |   | Review Date: | May 2024 |  |  |
| Endorsed<br>by:  | Medicines and Th  | nerapeutics Commit |          | Date:   | 19/05/2021   |          |  |  |
| NSQHS<br>Standards<br>Applicable:  | Std 1: Clinical Governance<br>Std 2: Partnering with Consumers<br>Std 3: Preventing and Controlling<br>Healthcare Associated Infection<br>Std 4: Medication Safety                                    |                    |          | <ul> <li>Std 5: Comprehensive Care</li> <li>Std 6: Communicating for Safety</li> <li>Std 7: Blood Management</li> <li>Std 8: Recognising and<br/>Responding to Acute Deterioration</li> </ul> |              |          |  |  |
| Printed or personally saved electronic copies of this document are considered uncontrolled.<br>Access the current version from WNHS HealthPoint. |   |                    |          |   |              |          |  |  |

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

#### © Women and Newborn Health Service 2020

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.